Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF)

Equities research analysts at Noble Financial initiated coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a research report issued on Monday. The brokerage set an “outperform” rating and a $12.00 price target on the stock. Noble Financial’s price objective points to a potential upside of 346.93% from the company’s current price.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.13.

Cardiff Oncology Trading Up 0.9%

Shares of Cardiff Oncology stock traded up $0.03 during trading on Monday, reaching $2.69. The stock had a trading volume of 117,362 shares, compared to its average volume of 316,181. Cardiff Oncology has a 52 week low of $1.90 and a 52 week high of $4.99. The stock has a fifty day moving average price of $2.38 and a two-hundred day moving average price of $2.59. The company has a market capitalization of $180.86 million, a price-to-earnings ratio of -3.44 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. On average, equities analysts forecast that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

Institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL lifted its position in Cardiff Oncology by 44.1% during the second quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock valued at $7,951,000 after purchasing an additional 772,844 shares in the last quarter. Laurion Capital Management LP grew its holdings in Cardiff Oncology by 37.2% during the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after buying an additional 668,590 shares in the last quarter. Acorn Capital Advisors LLC raised its stake in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares in the last quarter. Flputnam Investment Management Co. lifted its position in Cardiff Oncology by 1,008.8% during the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock valued at $1,230,000 after purchasing an additional 543,370 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in Cardiff Oncology by 183.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 396,118 shares of the company’s stock valued at $1,244,000 after purchasing an additional 256,264 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.